In This Section

Program

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

[R] – remote presentation
*-Short talk from proffered abstract

Sunday, March 5, 2023

Welcome and Opening Keynote Lecture

Monday, March 6, 2023

Plenary Session 1: Biochemistry, Function, and Structure
Plenary Session 2: Signaling Networks
Plenary Session 3: Site-specific Session

Tuesday, march 7, 2023

Plenary Session 4: Metabolism
Plenary Session 5: RASopathies/RAS Superfamily
Plenary Session 6: Immunotherapy/Immunity

Wednesday, march 8, 2023

Plenary Session 7: Targeting RAS
Plenary Session 8: Resistance Mechanisms and Emerging Clinical Data
Closing Keynote Lecture

sunday, March 5, 2023

Registration
3:30-7:30 p.m.
Welcome and Opening KeynotE Lecture
6-7:30 p.m.

Welcome and Introduction of Keynote Speaker
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Keynote Lecture
Targeting KRAS: Inhibition versus degradation—lessons from mouse models

Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain

Welcome and Introduction of Rising Star Lecturer
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York

Rising Star Lecture
Targeting RAS in cancer: opportunities and challenges
Andrew Aguirre, Harvard Medical School, Boston, Massachusetts

Opening Reception
7:30-9:00 p.m.

Monday, march 6, 2023

Continental Breakfast
7-8 a.m.
Plenary Session 1: Biochemistry, Function, and Structure
8-10:15 a.m.
Session Chair: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Title to be announced
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced
Piro Lito, Memorial Sloan Kettering Cancer Center, New York, New York

Structural insights into RAS-effector complexes
Dhirendra K. Simanshu, Frederick National Laboratory for Cancer Research, Frederick, Maryland

Structural plasticity of KRAS oncogenic mutants – a case of misleading conclusions from GTP analogues*
Alok K. Sharma, Frederick National Laboratory for Cancer Research, Frederick, Maryland

Factors modulating RAF dimerization downstream of RAS – A mechanistic overview*
Jawahar Sudhamsu, Genentech Inc., South San Francisco, California

Break
10:15-10:35 a.m.
Plenary Session 2: Signaling Networks
Session Chair: Deborah K. Morrison, National Cancer Institute, Frederick, Maryland
10:35 A.M.-12:55 P.M.

Targeting the ERK-MYC signaling network for the treatment of KRAS-mutant cancers
Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Molecular characterization of acquired resistance to KRASG12C–EGFR inhibition in colorectal cancer
Sandra Misale, Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced
Rene Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Direct covalent inhibitors of mutant K-Ras
Kevan M. Shokat, University of California, San Francisco, California

Lunch on own/Free time
12:55-2:15 p.m.
Plenary Session 3: Tackling RAS Using a Disease-specific Approach
Session Chair: Christin E. Burd, The Ohio State University, Columbus, Ohio
2:15-4:30 p.m.

Allelic specificity: The key to NRAS-mutant melanoma initiation?
Christin E. Burd, The Ohio State University, Columbus, Ohio

K-RAS hyperexchange mutants in colorectal cancer
Kevin M. Haigis, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Laura D. Wood, Johns Hopkins University School of Medicine, Baltimore, Maryland

Title to be announced
Karen M. Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts

Poster Session A/Reception
4:45-7 p.m.

Tuesday, March 7, 2023

Continental Breakfast
7-8 a.m.
Plenary Session 4: Metabolism
Session Chair: Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
8-10:15 a.m.

Identifying metabolic dependencies in pancreatic cancer
Alec C. Kimmelman, New York University Langone Medical Center, New York, New York

Title to be announced
Tor Erik Rusten, Norwegian Radium Hospital, Oslo, Norway

Title to be announced
Rushika M. Perera, University of California, San Francisco, California

Cooperative anti-tumor effects of combined inhibition of KRASG12C plus autophagy in preclinical models of KRASG12C-driven lung cancer*
Phaedra C.  Ghazi, University of Utah, Salt Lake City, Utah

A bimodal mechanism of RAS inactivation by monoubiquitination*
Wout Magits, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium

Break
10:15-10:35 a.m.
Plenary Session 5: RASopathies/RAS Superfamily
Session Chair: Marco Tartaglia, Bambino Gesù Children’s Hospital, Rome, Italy
10:35 a.m.-12:50 p.m.

Title to be announced
Marco Tartaglia, Bambino Gesù Children’s Hospital, Rome, Italy

Use of RAS isoforms in nerve tumors
Nancy Ratner, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

Somatic predisposition to germline mutations in the RTK/RAS/MAPK pathway
Anne Goriely, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

The role of the RAS GTPase RIT1 in RASopathies and cancer*
Pau Castel, New York University School of Medicine, New York, New York

Germline RASopathy mutations provide insights into the differential regulation of RAF family kinases*
Russell Spencer-Smith, National Cancer Institute-Frederick, Frederick, Maryland

lunch on own/free time
12:50-2:15 p.m.
Plenary Session 6: RAS and Tumor Immunity
Session Chair: Julian Downward, The Francis Crick Institute, London, England
2:15-4:30 p.m.

Oncogenic KRAS and the regulation of the pancreatic cancer microenvironment
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan

The impact of RAS inhibition on tumor immune evasion
Julian Downward, The Francis Crick Institute, London, England       

Immune rewiring of mutant Ras tumors:  Mechanisms and translational implications
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York

Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma*
Rachael K. Baliira, University of Michigan, Ann Arbor, Michigan

TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development*
Adham S. Bear, University of Pennsylvania, Philadelphia, Pennsylvania

Poster Session B/Reception
4:45-7 p.m.

wednesday, March 8, 2023

Continental Breakfast
7-8 a.m.
Plenary Session 7: Targeting RAS
Session Chair: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
8-9:40 a.m.

Title to be announced
Shiva Malek, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts

Selectively targeting KRAS mutant alleles: contribution of both cell autonomous and pro-immunogenic MOAs in an expanded spectrum of human cancers 
James G. Christensen, Mirati Therapeutics, San Diego, California

KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models*
Kathryn Smith, Arvinas Operations, Inc., New Haven, Connecticut

IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers*
X. Michelle Zhang, Ikena Oncology, Boston, Massachusetts

BREAK
9:40-10 A.M.
Plenary Session 8: Resistance Mechanisms and Emerging Clinical Data
Session Chair: Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
10-11:45 A.M.

Title to be announced
Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, Tennessee

Systemic interrogation of KRAS function
William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts

Exploiting altered metabolism as a therapeutic strategy for RAS-driven cancers
Kirsten L. Bryant, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

break
11:45 a.m.-12 p.m.
Closing Keynote Lecture
12-12:50 p.m.

Introduction of Keynote Speaker
Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain

Title to be announced
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Closing Remarks and Departure
12:50 p.m.

Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York